Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
November 8, 2018 4:02 PM ESTAURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule Phase II data for the treatment of dry eye expected in January 2019 Phase II FSGS Trial ongoing Richard M. Glickman announces his intention to retire as CEO next year, upon identification and appointment of an appropriate successor
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (Aurinia or the Company) has released its financial results for the third quarter ended September... More
